A key strategy in the treatment of COVID-19 would be to find an effective antiviral agent
that would decrease the peak viral load and, consequently, the associated degree of
immunopathological damage that follows this phase. The clinically approved substances
considered for this study are used for treatment of other virus diseases, like HIV
(atazanavir) and HCV (sofosbuvir and daclatasvir). Severe progression of COVID-19 among
patients under treatment for these aforementioned viruses is empirical less common. Besides,
the clinical rationale, there are pre-clinical evidence pointing out that patients with
COVID-19 could benefit from treatments with atazanavir, sofosbuvir and daclatasvir.